Direct-Acting Oral Anticoagulants (DOACs) in Cirrhosis and Cirrhosis-Associated Portal Vein Thrombosis

Ethan M. Weinberg, MD1,* Julia Palecki, BA1,* K. Rajender Reddy, MD1

1 Division of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania


Abstract

Direct-acting oral anticoagulants (DOACs) have provided benefit in patients requiring anticoagulation for certain diseases by decreasing the burden of subcutaneous injections and the requirement for frequent monitoring through regular blood tests, to ensure adequacy of the therapeutic doses. Studies have demonstrated DOACs to be as safe, and in some instance safer, compared with traditional anticoagulants in the general population. However, the studies evaluating DOACs excluded patients with cirrhosis, a condition associated with an increased risk of developing portal vein thrombosis (PVT). Warfarin or low-molecular weight heparin are the standard-of-care treatment for acute PVT in cirrhosis, although there is enthusiasm in a paradigm shift switching to DOACs for the treatment of acute PVT in cirrhosis, particularly since the release of DOAC antidotes. This article reviews the current Food and Drug Administration-approved DOACs, hepatic metabolism of DOACs, pharmacokinetics of DOACs in patients with cirrhosis, safety of DOACs (including bleeding, hepatotoxicity, and pregnancy), current treatment guidelines for PVT in cirrhosis, and studies evaluating the use of DOACs in cirrhosis and for the treatment of PVT in cirrhosis. The potential use of DOACs for PVT primary prophylaxis in at-risk patients with cirrhosis and the possible antifibrotic effects of DOACs are also discussed.

Keywords

► portal vein thrombosis
► cirrhosis
► anticoagulation
► DOAC
► NOAC

There are two widespread fallacies pertaining to cirrhosis and anticoagulation: the first is that cirrhosis is a contraindication to anticoagulation due to an increased bleeding risk. The second is that those with an elevated international normalized ratio (INR) do not require anticoagulation because they are already “auto-anticoagulated.” Both of these common misconceptions among the medical community have recently been dispelled. Patients with cirrhosis are at similar risk as those without cirrhosis for clotting and other events, such as thromboembolic phenomenon in atrial fibrillation or venous thromboembolism (VTE) prevention during hospitalizations for acute illness, and as such receive anticoagulation with no added risk. However, the leading reason for anticoagulation in patients with cirrhosis is portal vein thrombosis (PVT). PVT has historically been classified into four categories: cirrhotic or noncirrhotic, acute or chronic, occlusive or nonocclusive, and malignant or nonmalignant. A 2016 paper proposed a new nomenclature for PVT to allow for precision of language and to aid in future clinical studies. PVT is being increasingly recognized in patients with cirrhosis, with higher incidence in those with decompensated cirrhosis. The clinical manifestations of PVT depend on the extent of the obstruction and the rapidity of development. Often, recent PVT is asymptomatic. However, patients may present with abdominal pain, often accompanied by splenomegaly, fever, and/or ascites—these would be categorized as acute. Chronic PVT
may be asymptomatic and discovered incidentally when abdominal imaging is obtained for other reasons, or may present with complications of portal hypertension such as ascites, gastrointestinal variceal bleeding, or even manifest with portal cholangiopathy. Over the past decade, there has been an increased understanding of the pathophysiology of PVT. However, there is a relative dearth of studies examining PVT in patients with cirrhosis compared with studies examining other decompensation events, such as ascites and hepatic encephalopathy. Additionally, while primary prophylaxis is well accepted to prevent events such as spontaneous bacterial peritonitis and variceal hemorrhage, with antibiotics and β blockers, respectively, primary prophylaxis with anticoagulants is less commonly used to prevent PVT in patients with cirrhosis, partially due to fear of bleeding complications. With the advent of new direct-acting oral anticoagulants (DOACs), the approach to the prevention and treatment of PVT is in transition. This review examines the approved uses, safety concerns, and potential role for DOACs in cirrhosis with a focus on their use for PVT. Additionally, a plausible additional role as an antifibrotic will be discussed.

**Risk for Thrombosis in Cirrhosis**

**Portal Vein Thrombosis**

The prevalence of PVT among those with cirrhosis has been estimated to be between 10 and 25%, with an increase in incidence being strongly associated with the severity of liver disease. Inherited prothrombotic disorders have been associated with an increased risk of developing PVT. For instance, the presence of the prothrombin (PT) gene mutation 20210 has been reported to increase the risk of PVT more than fivefold. Other thrombophilic gene mutations including antithrombin, protein C, and protein S deficiencies have also been implicated. Reduced portal flow velocity of less than 15 cm/s in patients with cirrhosis appears to have a significant predictive variable for the development of PVT (91.7 vs. 19.7%). Few studies have defined the natural course of acute and untreated nonmalignant PVT in those with cirrhosis and without interventions. A prospective cohort study of partial nonmalignant PVT without anticoagulant therapy found that, after a mean follow-up time of 20 months, PVT worsened in close to 30% of cases and correlated with increased rates of hepatic decompensations and death. Another prospective study on those with untreated nonmalignant PVT noted that, after a mean follow-up time of 27 months, the partial PVT progressed in almost 50% of patients and this correlated with the severity of cirrhosis. It is not clear if progression of a partially occluding PVT to completely occluding PVT leads to further hepatic decompensation or whether worsening liver disease is the nidus for a PVT to transition from partial to complete occlusion.

The most recent American Association for the Study of Liver Diseases (AASLD) guidelines for the management of PVT in cirrhosis were published in 2009; at that time, the AASLD committee did not provide specific anticoagulation guidance for PVT, but recommended clinical decisions be made on a case-by-case basis depending on the presence of prothrombotic conditions, symptoms, or extension into the superior mesenteric vein (SMV). The European Association for the Study of the Liver (EASL) guidelines on vascular disorders of the liver, published in 2016, recommends evaluating for the presence of at-risk varices and initiating therapy (either band ligation or nonselective β blocker) prior to initiation of anticoagulation treatment for PVT in cirrhosis. Similar to AASLD, EASL does not make broad recommendations on the choice of therapy for PVT, but that each institution/liver unit, should follow their own treatment algorithm until randomized trials have demonstrated a preferred drug. The risk and benefits of treatment with anticoagulation for PVT in cirrhosis have been debated for years. The purported benefits of anticoagulation can be divided into surrogate outcomes (recanalization of the portal vein and progression of PVT) and clinical outcomes (variceal bleeding, liver transplantation, and death) compared with the risks (bleeding associated due to anticoagulation). Loffredo et al compiled a meta-analysis evaluating the effects of traditional anticoagulation (no DOACs studies included) for PVT in cirrhosis, and reported that anticoagulation increased PV recanalization and decreased the incidence of PVT progression and variceal bleeding (though variceal bleeding improvements were limited to low-molecular-weight heparin [LMWH]). Additionally, it appears that the bleeding risk associated with anticoagulation treatment for PVT in cirrhosis is not statistically greater than no treatment at all. Studies large enough to evaluate the impact of anticoagulation treatment of PVT in cirrhosis in delaying liver transplantation and death have not yet been performed. However, the indirect benefits of anticoagulation for PVT in cirrhosis in liver transplant candidates can be inferred, as PVT at the time of liver transplant can increase surgical complications, including longer operative time and more intraoperative blood loss, and postoperative complications, including bleeding complications and recurrent PVT.

**Non-PVT Venous Thromboembolism**

A large U.S. inpatient database (the National Inpatient Sample) analysis noted that hospitalized patients with cirrhosis under 45 years old were more likely to experience non-PVT VTE than patients without cirrhosis. Hospitalized patients with cirrhosis that were diagnosed with a VTE had an average length of stay of more than double that of patients with cirrhosis and without a VTE. The presence of VTE increased in-hospital mortality rates among patients with and without cirrhosis. A different study employing the National Inpatient Sample (2005) found that patients with cirrhosis that were diagnosed with a VTE were, on average, more malnourished, but less likely to have complications of liver disease during that admission (variceal bleeding, ascites, or coagulopathy). In contrast, another large database study using discharge codes for chronic alcoholic and nonalcoholic liver disease found that patients with these diagnosis codes had low rates of VTE; however, these groupings included a large number of patients without cirrhosis.
Several small single-center reports have attempted to tease out the risk factors for VTE among patients with cirrhosis. Using a retrospective case–control approach, Northup et al were the first to evaluate the clinical characteristics of non-PVT VTE in hospitalized patients with cirrhosis, finding no difference in the INR between patients with cirrhosis that are diagnosed with a VTE and the controls; the VTE cases had lower serum albumin than the controls.\(^2\) Four additional case–control studies reported that patients with chronic liver disease that experience VTE had lower serum albumin, although this has not been corroborated in prospective studies.\(^24-26\) Another single-center retrospective study demonstrated an increase in incidence of VTE in hospitalized patients with cirrhosis based on Child–Turcotte–Pugh (CTP) class, but not based on INR.\(^27\) The authors noted that an astounding 75% of the patients did not receive any form of anticoagulation prophylaxis (mechanical/compression stockings or pharmacologic).\(^27\) While patients with cirrhosis that experience a VTE had a higher 30-day mortality risk than those without cirrhosis, the proportion of deaths attributable to pulmonary embolism (PE) appeared to be the same in each group.\(^28\) It is these studies that have helped debunk the “auto-anticogulation” belief that is widely perceived in clinical care.

**Mechanism of Thrombosis and Role of DOACs as Antifibrotic Agents**

There is a growing body of literature that demonstrates the interconnection between liver disease progression and prothrombotic states within the liver and portal system. In cirrhosis, there is a rebalancing of both pro- and anticoagulant factors that increase the risk for both bleeding and thrombosis (Fig. 1).\(^1\) While there is a decrease in PT production and, thus, less thrombin formation in cirrhosis, there is a simultaneous decrease in antithrombin production.\(^29\) Kremers et al noted that the PT–thrombin–antithrombin equilibrium is altered in the patient with cirrhosis such that thrombin is formed more quickly and inactivated more slowly than in a healthy control.\(^29\) The change in thrombin kinetics in cirrhosis is a necessary adaptation in the setting of diminished levels of PT and antithrombin; however, the prolongation of activated thrombin may be further promoting liver fibrosis. Hepatic stellate cells (HSCs), the drivers of fibrosis in liver disease, upregulate thrombin receptors in response to liver injury.\(^30\) The increased half-life of thrombin paired with an increase of its receptors on HSCs may perpetuate liver damage in cirrhosis.\(^30,31\) Indeed, in vivo studies using dabigatran and argatroban, both Food and Drug Administration (FDA)-approved thrombin inhibitors, demonstrate antifibrotic effects in the skin, lung, and liver.\(^32-35\) Studies from the Luyendyk laboratory demonstrated in two separate mouse models of fatty liver disease that both argatroban and dabigatran decreased inflammation and subsequent fibrosis associated with steatohepatitis.\(^33,34\)

Inhibiting targets further along in the coagulation cascade also appears to prevent further liver injury in vivo models. The most studied of these targets is factor Xa. LMWHs (enoxaparin and dalteparin) have historically been the most commonly used factor Xa inhibitors in studies focusing on liver fibrosis given their ease of administration compared with heparin, its cost, and well-known safety profile compared with the newer DOACs. LMWH has been demonstrated to decrease liver fibrosis in chemically induced liver fibrosis and cirrhosis rat models.\(^36,37\) There are conflicting data on the effects of LMWH and DOACs on portal hypertension in cirrhosis rat models.\(^38-40\) One group has demonstrated that both enoxaparin and rivaroxaban decreased portal hypertension and fibrosis in the rat cirrhosis model. It was hypothesized that these effects are mediated through deactivation of HSCs, as desmin and α-smooth muscle actin were both decreased in the rats treated with a factor Xa inhibitor.\(^40\) However, another study demonstrated no improvements in portal hypertension in cirrhotic rats treated with enoxaparin.\(^39\) Like thrombin, inhibition of factor Xa has also been linked to decreased fibrosis formation in the skin, but at the cost of decreased wound healing.\(^41\)

While most factors in the coagulation cascade are reduced in end-stage liver disease, von Willebrand factor (VWF) is increased.\(^1\) Higher levels of VWF are correlated with portal hypertension, hepatic decompensations, and death.\(^42\) Increased VWF activity has been associated with poor clinical outcomes in patients with acute-on-chronic liver failure.\(^43\) Depletion of VWF in in vivo mice models of acute liver injury resulted in decreased liver fibrosis.\(^44\) In contrast, ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13), a VWF cleaving enzyme, is often decreased in cirrhosis. A study evaluating the effects of ADAMTS13 in a mouse model of nonalcoholic fatty liver disease demonstrated that ADAMTS-13 deficiency led to increased fibrosis and microthromboses in the liver.\(^45\) An exploratory study evaluating coagulation factors in patients with PVT demonstrated a significant increase in VWF and decrease in ADAMTS-13 activity among those patients with PVT compared with matched controls of patients with cirrhosis.\(^46\) Based on many of the in vivo and human studies, it seems that therapeutic targeting of a component of the coagulation cascade could help to ameliorate end-stage liver disease while also preventing PVT.

Villa et al performed a randomized controlled trial to evaluate the safety and efficacy of enoxaparin in preventing...
PVT in patients with advanced cirrhosis, defined as Child–Pugh class B7-C10.47 Patients treated with enoxaparin demonstrated significantly lower incidence of PVT at all time points evaluated (at 48 weeks [0 vs. 16.6%, \(p = 0.025\)], at 96 weeks [0 vs. 27.7%, \(p = 0.001\]), and at the end of the follow-up period [8.8 vs. 27.7%, \(p = 0.048\)].47 Most importantly, patients treated with enoxaparin demonstrated lower rates of liver decompensation (11.7 vs. 59.4%, \(p < 0.0001\)) and lower mortality (8/34 vs. 13/36), suggesting that enoxaparin may delay hepatic decompensation and improve survival.47 There were three bleeding episodes from ruptured esophageal varices, two of which occurred in the treatment group, and three episodes of epistaxis, two of which occurred in the treatment group.47 Overall, this trial concluded that anticoagulant therapy was safe and effective in preventing PVT in patients with cirrhosis and also that such intervention improved survival.47

Approved Uses for DOACs

The pharmacology of traditional anticoagulants, DOACs, and their effects on the coagulation cascade has been written about extensively.48 Briefly, warfarin antagonizes vitamin K, which is a necessary cofactor for factors II, VII, XI, and X, and requires frequent monitoring of levels. Heparin and LMWH function as indirect inhibitors of factor Xa. Rivaroxaban, apixaban, edoxaban, and betrixaban inhibit factor Xa directly. Dabigatran acts as a direct thrombin inhibitor (Fig. 2).

There are currently five FDA-approved DOACs: dabigatran (Pradaxa, direct thrombin inhibitor), rivaroxaban (Xarelto, factor Xa inhibitor), apixaban (Eliquis, factor Xa inhibitor), betrixaban (Bevyxxa, factor Xa inhibitor), and edoxaban (Savaya, factor Xa inhibitor). DOACs are also referred to as target-specific oral anticoagulants or novel oral anticoagulants (NOACs) or non-vitamin K oral anticoagulants (VKA); however, the term NOAC may be falling out of favor, as NOAC has been mistaken for NO AC (i.e., no anticoagulation) and inadvertently stopped in patients.49 The designation DOAC distinguishes these medications from warfarin, which acts as an indirect oral anticoagulant through vitamin-K antagonism, and direct-acting anticoagulants in solution that are given as injections (either intravenous or subcutaneous).

Direct-acting oral anticoagulants as a class have been approved for the following uses: prevention of thromboembolic phenomenon in atrial fibrillation, VTE prevention in patients undergoing hip or knee replacement and in patients hospitalized for acute illness, and as treatment of VTE or PE and prevention of recurrence of VTE or PE. For each drug and approved indication, one or more large phase III studies were performed that included many patients in numerous countries.50–65 In general, DOACs (at the approved doses) were found to be noninferior or slightly superior in preventing thromboembolic events compared with the existing standard-of-care in each trial—either warfarin or LMWH.66,67 In each of these trials, patients with abnormal hepatic biochemical tests, active liver disease, or cirrhosis were often excluded. Additionally, phase III trials for apixaban, dabigatran, edoxaban, and betrixaban all excluded patients with platelet counts less than 100,000 cells/μL. Rivaroxaban trials did not have a strict platelet threshold, but one did exclude patients with “hepatic disease which is associated with coagulopathy leading to a clinically relevant bleeding risk,” which would include those with undiagnosed cirrhosis and likely portal hypertension.59

Hepatic Metabolism and Pharmacokinetics of DOACs in Cirrhosis

Although four of the five currently approved DOACs have the same target—factor Xa—the metabolism and pharmacokinetics (PKs) of these drugs differ (Table 1). Rivaroxaban is

Fig. 2 Sites of action for commonly used anticoagulants.
Table 1 DOAC hepatic metabolism, pharmacokinetics, and effects on INR

<table>
<thead>
<tr>
<th>Mechanism of action</th>
<th>Rivaroxaban</th>
<th>Apixaban</th>
<th>Edoxaban</th>
<th>Betrixaban</th>
<th>Dabigatran</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatic metabolism</td>
<td>++</td>
<td>++</td>
<td>+++</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td>Peak drug levels ($C_{max}$)</td>
<td>↑</td>
<td>–</td>
<td>↓</td>
<td>NR</td>
<td>↓↓</td>
</tr>
<tr>
<td>Drug exposure (AUC)</td>
<td>↑↑</td>
<td>–</td>
<td>↓↓</td>
<td>NR</td>
<td>↓↓</td>
</tr>
<tr>
<td>Effect on INR</td>
<td>↑↑</td>
<td>↑</td>
<td>NR</td>
<td>NR</td>
<td>↑</td>
</tr>
</tbody>
</table>

Abbreviation: AUC, area under the curve; CTP, Child–Turcotte–Pugh; DOAC, direct-acting oral anticoagulant; INR, international normalized ratio; NR, not reported.

Note: Arrows signify relative change. Data from Graff and Harder, 2013 and Bunchorntavakul and Reddy, 2017.

processed through both the liver and kidneys, with about two-thirds of the drug metabolized by the liver via cytochrome P450 isoenzymes (CYP), to inactive metabolites. Kubita et al performed a PK study evaluating a single dose of rivaroxaban in patients with CTP class A and B. Compared with healthy controls, a single dose of rivaroxaban had slightly increased exposure in CTP-A (area under the curve [AUC]: 1.15), but moderately increased in CTP-B (AUC: 2.27), leading to longer inhibition of factor Xa in CTP-B. Additionally, rivaroxaban led to increases in PT in CTP-B. Apixaban undergoes both hepatic metabolism (through multiple CYPs) and renal and intestinal excretion. Peak drug levels of a single dose of 5 mg apixaban were not changed in CTP-A and CTP-B compared with healthy controls; drug exposure was slightly elevated (AUC: 1.03 and 1.09, respectively). Apixaban leads to increased PT in both CTP-A and CTP-B.

Edoxaban is metabolized in the liver through CYP3A4 and also undergoes renal excretion. Though requiring significant hepatic metabolism, edoxaban demonstrated decreased peak levels and drug exposure in CTP-A and CTP-B patients compared with healthy controls. Edoxaban increased PT in healthy volunteers, but data on the effects of PT in patients with cirrhosis is lacking. Dabigatran does not undergo considerable CYP processing in the liver and is mostly excreted through the kidneys as active dabigatran. Dabigatran peak levels ($C_{max}$) and exposure (AUC) were slightly lower (but not statistically significant) in CTP-B patients compared with healthy controls after a single dose of 150 mg dabigatran. Betrixaban varies markedly from the other factor Xa inhibitors in its metabolism, as it is primarily excreted through the intestines after undergoing passage through P-glycoprotein pumps and undergoes minimal hepatic metabolism or renal excretion. A phase I trial evaluating the PKs of betrixaban in CTP-A and CTP-B was completed in early 2018, but results have not yet been released.

DOACs evaluating the PKs in patients with CTP-C. Rivaroxaban, apixaban, dabigatran, and betrixaban have undergone PK studies in CTP-B patients (though for betrixaban has not yet been published).

DOACs for Treatment of PVT in Cirrhosis

Direct-acting oral anticoagulants have not been extensively studied in patients with cirrhosis. A few studies have investigated the safety and efficacy of DOACs in patients with cirrhosis with indications for anticoagulant therapy including atrial fibrillation, VTE, and PVT (see Table 2). DOACs were noted to have similar safety profiles as traditional anticoagulants (i.e., warfarin, heparin, and LMWH) in these groups, demonstrated by the comparable rates of bleeding complications in patients receiving DOACs and those receiving traditional anticoagulants.

Numerous case studies have reported on the use of DOACs in patients with cirrhosis for the treatment or prevention of recurrence of PVT. In the majority of cases, treating portal system VTE (including partial/complete PVT, SMV, or both) with DOACs successfully resulted in partial/complete resolution of the thrombus.

While there has not yet been a randomized control trial comparing the safety and efficacy of DOACs versus traditional anticoagulation for the treatment of PVT in cirrhosis, Nagaoki et al recently published a historical comparison at a single institution comparing maintenance treatment of edoxaban and warfarin in cirrhotic patients with acute PVT. All patients received 2 weeks of intravenous danaparoid prior to OAC. Patients diagnosed prior to November 2014 received warfarin therapy ($n$ = 30); those afterwards received edoxaban ($n$ = 20), with patients receiving OAC for up to 6 months. A significantly larger percentage of patients receiving edoxaban compared with warfarin achieved complete resolution of PVT (70% vs. 20%). Additionally, a smaller percentage of patients receiving edoxaban
<table>
<thead>
<tr>
<th>Name, Year, Title</th>
<th>Indications for anticoagulation therapy</th>
<th>Drug, dose</th>
<th>Number of patients</th>
<th>Efficacy</th>
<th>Safety</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intagliata et al, 2016</td>
<td>Splanchnic thrombosis, non-splanchnic venous thromboembolism, and atrial fibrillation</td>
<td>DOAC (factor Xa inhibitors; rivaroxaban and apixaban) versus traditional anticoagulants (warfarin and LMWH)</td>
<td>DOAC, n = 20, Warfarin, n = 19</td>
<td>—</td>
<td>DOACs had similar safety characteristics to traditional anticoagulants in cirrhotic patients. 3 bleeding events in the traditional anticoagulation group and 1 major bleeding event in the DOAC group; no documented report of DILI</td>
</tr>
<tr>
<td>Hum et al, 2017</td>
<td>Atrial fibrillation or venous thromboembolism, including PVT and deep vein thrombosis</td>
<td>DOAC (apixaban and rivaroxaban) versus traditional anticoagulants (LMWH and vitamin-K antagonist)</td>
<td>DOAC, n = 27, Warfarin/LMWH, n = 18</td>
<td>Efficacy analysis: only one patient in each group where the therapeutic anticoagulation failed, both with progression of DVT while on therapy. No ischemic strokes or progression of PVT in either group</td>
<td>—</td>
</tr>
<tr>
<td>De Gottardi et al, 2017</td>
<td>Splanchnic vein thrombosis, deep vein thrombosis, atrial fibrillation, and others</td>
<td>DOACs used were rivaroxaban (83%), dabigatran (11%), and apixaban (6%)</td>
<td>Cirrhosis, n = 36</td>
<td>A consistent number of patients with SVT and/or cirrhosis were currently treated with DOACs, which seemed to be effective and safe</td>
<td>Adverse events occurred in 17% of patients including 1 case of recurrent PVT and 5 cases of bleeding</td>
</tr>
<tr>
<td>De Gottardi et al, 2015</td>
<td>SVT, peripheral deep vein thrombosis, Budd–Chiari syndrome, atrial fibrillation, and others</td>
<td>DOACs used were rivaroxaban (31), dabigatran (3), and apixaban (1) for a medium of 7 mo</td>
<td>DOAC use in patients with SVR and/or cirrhosis = 35</td>
<td>—</td>
<td>Adverse events: 1 case of anemia, 1 dizziness/disorientation, and 1 progression of SVR; 1 patient on rivaroxaban was stopped due to HRS. DOACs seemed to be safe b/c no major bleeding episodes of liver deterioration occurred during treatment</td>
</tr>
<tr>
<td>Name, Year Title</td>
<td>Indications for anticoagulation therapy</td>
<td>Drug, dose</td>
<td>Number of patients</td>
<td>Efficacy</td>
<td>Safety</td>
</tr>
<tr>
<td>------------------</td>
<td>----------------------------------------</td>
<td>------------</td>
<td>--------------------</td>
<td>----------</td>
<td>--------</td>
</tr>
<tr>
<td>Nagaoki et al 2018&lt;sup&gt;78&lt;/sup&gt; Edoxaban versus warfarin for treatment of PVT in cirrhosis</td>
<td>Portal vein thrombosis</td>
<td>Edoxaban 60 mg (CrCl &gt; 50), Edoxaban 30 mg (CrCl 30–50), Warfarin, INR 1.5–2.0</td>
<td>Edoxaban, n = 20 Warfarin, n = 30</td>
<td>Edoxaban group had more complete resolution and less PVT progression</td>
<td>Adverse events: 3 GI bleed (edoxaban), 2 GI bleed warfarin</td>
</tr>
<tr>
<td>Pastori et al, 2018&lt;sup&gt;81&lt;/sup&gt; VKA vs. DOACs on bleeding incidence in atrial fibrillation with advanced liver fibrosis</td>
<td>Atrial fibrillation</td>
<td>DOAC (does not specify type or dose), warfarin</td>
<td>DOAC, n = 52 Warfarin, n = 77</td>
<td>DOAC group had less cerebrovascular events</td>
<td>DOAC group had significantly less major and minor bleeding events</td>
</tr>
<tr>
<td>Scheiner et al, 2018&lt;sup&gt;80&lt;/sup&gt; Anticoagulation in nonmalignant portal vein thrombosis is safe and improves hepatic function</td>
<td>Portal vein thrombosis (cirrhotic and noncirrhotic)</td>
<td>Edoxaban 30/60 mg, Apixaban 5 mg, Rivaroxaban 10 mg, Dabigatran 110 mg</td>
<td>Edoxaban, n = 4 Apixaban, n = 3 Rivaroxaban, n = 2 Dabigatran, n = 1</td>
<td>20% with resolution of PVT, 80% with stable of cavernoma</td>
<td>One event of portal hypertensive gastropathy bleeding in the DOAC group</td>
</tr>
<tr>
<td>Hanafy et al, 2018&lt;sup&gt;79&lt;/sup&gt; Randomized controlled trial of rivaroxaban versus warfarin in the management of acute nonneoplastic portal vein thrombosis</td>
<td>Acute portal vein thrombosis after splenectomy or abdominal infection</td>
<td>Rivaroxaban 10 mg, Warfarin, target INR 2.0–2.5</td>
<td>Rivaroxaban, n = 40 Warfarin, n = 40</td>
<td>85% recanalization with rivaroxaban vs. 45% with warfarin</td>
<td>Eight deaths in the warfarin group; none in the rivaroxaban group</td>
</tr>
<tr>
<td>Janczak et al, 2018&lt;sup&gt;82&lt;/sup&gt; Rivaroxaban and apixaban for initial treatment of acute venous thromboembolism of atypical location</td>
<td>Venous thromboembolism in splanchnic veins, ovarian veins, renal veins, cerebral venous sinuses</td>
<td>Rivaroxaban, apixaban, enoxaparin (doses not specified)</td>
<td>Splanchnic vein: DOAC, n = 26 Enoxaparin, n = 23</td>
<td>No difference in recurrence rate of VTE between groups</td>
<td>No difference in bleeding rates between DOAC and LMWH.</td>
</tr>
</tbody>
</table>

Abbreviations: CrCl, creatinine clearance; DILI, drug-induced liver injury; DOAC, direct-acting oral anticoagulant; DVT, deep vein thrombosis; GI, gastrointestinal; HRS, hepatorenal syndrome; INR, international normalized ratio; LMWH, low-molecular weight heparin; PVT, portal vein thrombosis; SVR, sustained virological response; SVT, splanchnic vein thrombosis; VKA, vitamin K antagonist; VTE, venous thromboembolism.
had progression of PVT (5% vs. 47%). Only five patients had major bleeding events; the study was not powered to evaluate for a difference in bleeding rate. Hanafy et al recently reported their findings comparing rivaroxaban to warfarin for the treatment of acute PVT in a unique Egyptian population with hepatitis C cirrhosis that had mostly undergone splenectomy for symptomatic hypersplenism within 1 week prior to enrollment.79 The patients receiving rivaroxaban achieved recanalization of the portal vein at much higher rates (34/40) compared with those receiving warfarin (18/40).79 There were no reported hepatic decompensations or death in the rivaroxaban group, while patients in the warfarin group experienced ascites, gastrointestinal bleeding, encephalopathy, and death.79

The EASL PVT guidelines have a section devoted to treating PVT in cirrhosis with DOACs, but recommend caution given the paucity of data on this subject and the reported cases of hepatotoxicity in patients on rivaroxaban.14 Currently, clinical trials are being conducted to investigate the safety and efficacy of rivaroxaban for the primary and secondary prevention of PVT in cirrhotic patients.89,90 These trials are evaluating the prophylactic use of DOACs to prevent initial or recurrent PVT by measuring the incidence of thromboembolic events, while also monitoring for safety outcomes, providing more insight into the efficacy/safety of DOAC therapy in patients with cirrhosis and help guide clinical practice. Table 3 summarizes the salient advantages and disadvantages of three anticoagulant classes—DOACs, LMWH, and VKA. While in the Villa et al study no patients in the enoxaparin arm developed a PVT, it remains to be seen how many PVTs could be prevented with prophylactic use of DOACs. Ponziani et al reported on a patient with cryptogenic cirrhosis that developed a PVT while on rivaroxaban for atrial fibrillation. This patient was subsequently switched to LMWH, but the PVT underwent cavernous transformation despite therapy.91

**DOACs in Pregnancy and Lactation**

Direct-acting oral anticoagulants are not currently recommended for use during pregnancy; this is unlikely to change given the experience and safety of LMWH, which does not cross the placenta.92 Bapat et al evaluated the transplacental PKs of dabigatran, rivaroxaban, and apixaban using a dual perfusion ex vivo full-term human placenta model.93–95 Dabigatran crossed into the fetal circulation slowly, reaching 17% of the maternal levels after 3 hours.93 On the other hand, rivaroxaban and apixaban moved quickly into the fetal circulation in this model, reaching 69% and 77%, respectively, of the maternal circulation drug levels at 3 hours.94,95 Hoeltzenbein et al composed a case series of outcomes in pregnant patients exposed to rivaroxaban.96 All women in this series discontinued rivaroxaban after learning of their pregnancy.96 Of the 37 pregnancies, there were 23 live births; one had severe congenital cardiac malformation (electively terminated) in a patient with systemic lupus erythematosus on numerous other medications that had a history of a fetal cardiac

---

**Table 3** Comparison of different anticoagulants for PVT in cirrhosis

<table>
<thead>
<tr>
<th></th>
<th>DOACs</th>
<th>LMWH</th>
<th>Warfarin</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Safety</strong></td>
<td>Appear as safe as warfarin and LMWH</td>
<td>Safety risks well-documented</td>
<td>Safety risks well-documented</td>
</tr>
<tr>
<td><strong>Clinical experience</strong></td>
<td>Short track record: Approved in 2010 (dabigatran)</td>
<td>Long track record: Approved in 1993</td>
<td>Longest track record: Approved in 1954</td>
</tr>
<tr>
<td><strong>Efficacy</strong></td>
<td>May be more effective than warfarin for PVT resolution</td>
<td>May be more effective than warfarin for PVT resolution</td>
<td></td>
</tr>
<tr>
<td><strong>Monitoring</strong></td>
<td>Marketed as not necessary, but more information is needed</td>
<td>Not necessary</td>
<td>Lifelong</td>
</tr>
<tr>
<td><strong>Wash out period</strong></td>
<td>~2 d</td>
<td>~2–3 d</td>
<td>~5–7 d</td>
</tr>
<tr>
<td><strong>FDA-approved for indication</strong></td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td><strong>Antidote</strong></td>
<td>Expensive and not widely available</td>
<td>Expensive and not widely available</td>
<td>Cheap antidote and widely available</td>
</tr>
<tr>
<td><strong>Route of administration</strong></td>
<td>Oral</td>
<td>Injection</td>
<td>Oral</td>
</tr>
<tr>
<td><strong>Pharmacokinetic studies in cirrhosis published</strong></td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td><strong>Hepatotoxicity</strong></td>
<td>Rates vary with DOAC—highest with rivaroxaban</td>
<td>Extremely rare</td>
<td>Rare</td>
</tr>
<tr>
<td><strong>Antifibrotic effects and evidence</strong></td>
<td>Possible, animal studies</td>
<td>Possible, clinical trial</td>
<td>Possible, animal studies</td>
</tr>
</tbody>
</table>

Abbreviations: DOAC, direct-acting oral anticoagulant; FDA, Food and Drug Administration; LMWH, low-molecular-weight heparin; PVT, portal vein thrombosis.
malformation (electively terminated) in a previous pregnancy prior to taking rivaroxaban.96

Compiling data from numerous types of sources (literature, study groups, government agency pharmacovigilance, and industry pharmacovigilance), Beyer-Westendorf et al sought to evaluate the pregnancy outcomes in women exposed to DOACs during pregnancy.97 Of the 233 reported DOAC exposures in pregnancy, only 59% (n = 137) had an available outcome, with about half (n = 67) of those leading to live births.97 Most women in this cohort were prescribed DOACs for the treatment of VTE and discontinued the DOAC within 2 months of becoming pregnant.97 The miscarriage rate for pregnant women on DOACs was 22%, which is similar to the general population, and less than with warfarin (30%).97 The authors noted three possible drug-related anatomical abnormalities, but were unable to deduce a pattern and were unable to provide new recommendations based on their observations.

Direct-acting oral anticoagulants are also not recommended for use in lactating women. A preclinical rat model using radiolabeled apixaban demonstrated that apixaban reached higher concentration in milk than in blood or plasma, with peak milk concentrations at 6 hours postigestion.98 The authors estimated that baby rats could receive up to 10% of the maternal dose through breast milk ingestion.98 Wiesen et al capitalized on a rare situation when a lactating woman was diagnosed with a lower extremity VTE in their hospital.99 The patient had ceased breastfeeding due a postpartum cardiomyopathy and was treated initially with enoxaparin followed by rivaroxaban.99 During weaning, breast milk samples were collected for analysis of rivaroxaban levels.99 Rivaroxaban concentration in the milk reached 40% of the plasma drug concentration, with the estimated relative infant dose to be 1.3%—well below the proposed acceptable 10% exposure concentration.99 It remains to be seen whether some DOACs will eventually be determined to be safe for use in lactating women.

**Direct-Acting Oral Anticoagulant Safety**

**Direct-Acting Oral Anticoagulants and Bleeding**

In addition to the efficacy of DOACs in preventing primary or secondary VTE and emboli, a primary concern of these medications is the bleeding risk. Ruff et al composed a meta-analysis of four phase III randomized trials in which DOACs (rivaroxaban, apixaban, edoxaban, and dabigatran) were evaluated for the prevention of embolic events in patients (n = 71,683) with atrial fibrillation.100 In each of these trials, warfarin was used as the standard-of-care comparison. Overall, patients receiving DOACs in these trials experienced less hemorrhagic stroke and intracranial bleeding, translating into improved mortality compared with those receiving warfarin.100 However, patients receiving warfarin experienced less gastrointestinal bleeding than those randomized to DOACs, while those on DOACs experienced fewer composite major bleeding events.100

More recently, large-scale postmarketing studies using large health care databases (national health care or insurance systems) comparing the safety of DOACs to warfarin have provided real-world data. Using the MarketScan database, Coleman et al found that apixaban and dabigatran performed similarly to warfarin in patients with atrial fibrillation and a prior ischemic stroke or transient ischemic attack (TIAs) while on anticoagulation for secondary prophylaxis, in regards to stroke prevention and major bleeding risk.101 Patients on rivaroxaban had suffered fewer strokes and TIAs than those on warfarin without an increase in bleeding.101 Though also using the MarketScan database, Lip et al found slightly different outcomes for major bleeding events in patients on anticoagulation with DOACs compared with warfarin for atrial fibrillation.102 Lip et al reported a decreased major bleeding risk with apixaban compared with warfarin, while dabigatran and rivaroxaban performed similarly to warfarin.102 Jacobs et al described decreased major bleeding events, strokes, and death in a matched cohort of patients receiving DOACs compared with warfarin in the Intermountain Healthcare system.103

Health care providers, not uncommonly, encounter patients on anticoagulation in the setting of a gastrointestinal bleed. A phase III study evaluating dabigatran for patients with atrial fibrillation found a small, but significant increase in gastrointestinal bleeding in patients receiving the higher dose of dabigatran (150 mg twice daily) compared with those receiving warfarin or the lower dose of dabigatran (110 mg twice daily).55 In addition, patients receiving either dose of dabigatran had higher rates of gastrointestinal symptoms and dyspepsia, compared with warfarin.55 The authors point out that the increase in gastrointestinal side effects is likely a result of the dabigatran formulation.55 A low pH is needed for dabigatran absorption; to decrease the pH around the drug, dabigatran pellets are wrapped in tartaric acid, which can lead to dyspepsia or ulcerations at any point in the gastrointestinal tract.55 As a result of the wrapped formulation, dabigatran cannot be crushed, unlike other DOACs which are not dependent upon an acidic environment.

Two studies using United States insurance claims databases found no significant difference overall in DOACs (rivaroxaban and dabigatran) compared with warfarin in gastrointestinal bleeding events, but cautioned that patients older than 75 years on DOACs had increased gastrointestinal bleeding rates compared with patients older than 75 years on warfarin.104,105 Cangemi et al, using the Veterans Affairs database, observed much lower rates of gastrointestinal bleeding among patients receiving DOACs than those on warfarin.106 Therapeutic endoscopy inherently carries a higher bleeding rate than diagnostic endoscopy. Nagata et al employed the Japanese national health care system claims database to evaluate postprocedure complications after therapeutic endoscopy for those on anticoagulation.107 Patients on DOACs experienced less postendoscopy bleeding than those on warfarin; VTE and mortality did not differ between the two groups.107 It is important to note that none of the studies listed above contained enough patients with cirrhosis to make additional claims for the cirrhosis subgroup.
Direct-Acting Oral Anticoagulants and Monitoring
While the main appeal of DOACs has been the claim that drug monitoring is not necessary, there has been some controversy over this issue. Reilly et al reported increased bleeding rates and decreased stroke rates among patients with higher plasma concentrations of dabigatran; those who tended to have higher plasma concentrations of dabigatran were older, had worse renal function, weighed less, and were female. The corollary was also true—those patients with lower dabigatran plasma concentrations were more likely to have an ischemic stroke and less likely to have major bleeding. However, it is unknown if hepatic impairment would further alter dabigatran plasma concentration given its lack of metabolism by the liver. Similar studies evaluating the effect of plasma concentration on serious adverse events from large trials have not been published for other DOACs, but that does not mean that it is not a concern.

Direct-Acting Oral Anticoagulants and Drug-Induced Liver Injury
Aside from bleeding events, another safety concern is of drug-induced liver injury (DILI) associated with DOACs. Caldeira et al performed a meta-analysis of 29 large-scale randomized controlled trials (n = 152,116) comparing DOACs to standard-of-care and found no significant difference in DILI events among the groups. In fact, patients receiving DOACs had significantly fewer instances of elevated hepatic biochemical tests compared with LMWH. However, real-world data suggest that rivaroxaban may have higher rates of DILI compared with other DOACs and warfarin. Concomitant use of statins, amiodarone, and acetaminophen were reported in about two-fifths of rivaroxaban-attributable DILI. Rivaroxaban-induced liver injury is likely drug-specific rather than class-specific, exemplified by a case in which a patient with atrial fibrillation had a severe hepatocellular injury with development of hepatic steatosis after initiation of rivaroxaban that resolved with a switch to apixaban. Dabigatran, apixaban, and edoxaban have also been associated with DILI, though less reported than rivaroxaban.

Direct-Acting Oral Anticoagulant Antidotes
A common reason for clinicians not to switch a patient from warfarin to DOAC has been the concern about antidote for major bleeding associated with DOACs. The antidote for warfarin—vitamin K—has been available longer than warfarin itself. For patients on warfarin with significant bleeding that does stop with vitamin K administration or bleeding that is located at a critical site or is life-threatening, the most recent multidisciplinary guidelines recommend administration of four-factor PT complex (4F-PCC) concentrate over plasma (fresh frozen, frozen, or thawed) given smaller volume of administration and the rapidity of INR correction with 4F-PCC over plasma. Idarucizumab, a monoclonal antibody fragment that binds dabigatran, was the first FDA-approved corrective specifically designed for any DOAC. Idarucizumab was approved in 2015 based on an interim analysis demonstrating rapid normalization of dilute thrombin time or ecarin clotting time in patients requiring reversal of dabigatran-induced anticoagulation due to serious bleeding or need for an urgent procedure. The full cohort analysis of idarucizumab for reversal of dabigatran, published in 2017, confirmed the interim findings. Most recently, in May 2018, andexanet (a recombinant factor Xa protein decoy) was approved as an antidote to factor Xa inhibitors rivaroxaban and apixaban based on an open-label study evaluating hemostasis in patients on factor Xa inhibitors with major bleeding event. While andexanet is currently approved only for reversal of rivaroxaban and apixaban, a trial is ongoing evaluating its effects on enoxaparin and edoxaban as well. In cases when a specific antidote for any anticoagulant is not available or is insufficient in providing necessary hemostasis, 4F-PCC is the recommended treatment; if a DOAC has been ingested within 4 hours of presentation, activated charcoal should also be considered. While it is highly likely that idarucizumab and andexanet provide necessary hemostasis in emergency settings for patients with cirrhosis, the rate of serious adverse events, particularly splanchnic thrombosis, are not known and will need to be followed through postmarketing registries.

Conclusion
It is understandable that the gastroenterology and hepatology community has not quickly embraced DOACs. However, this delay in DOAC adoption does not mean that DOACs are inferior to traditional anticoagulants; simply that more data are needed on the safety of DOACs in cirrhosis, although warfarin and LMWH became standard of care with limited data and poorly done studies. Patients with cirrhosis are at increased risk of bleeding compared with the general population and often have decreased platelet counts as a result of their liver disease. Interestingly, none of the currently FDA-approved DOACs mention platelet thresholds or warning for patients with thrombocytopenia in their prescribing information despite excluding these patients in the large trials. Given the tremendous variability in the liver’s role in metabolism of each DOAC, it is likely that some DOACs may be safer for those with cirrhosis than others. PK studies of rivaroxaban demonstrated increased drug exposure among CTP-B patients, but other studies have suggested possible decreased exposure of rivaroxaban in cirrhosis. Additionally, rivaroxaban has higher reported rates of hepatotoxicity than other DOACs. These two factors suggest that rivaroxaban is not the ideal DOAC for patients with cirrhosis. There has not yet been a PK study reported for CTP-C patients for any DOAC. For those with compensated cirrhosis (CTP-A), well-designed randomized control trials are needed to evaluate the safety and efficacy of DOACs for the treatment of PVT. It does appear that there is consensus on screening and treatment of esophageal varices prior to initiation of anticoagulation for PVT, but the best timeframe and method for variceal treatment prior to initiation of DOAC will need to be determined. Since the progression of PVT has been linked to increased hepatic decompensation events and even
mortality, prompt treatment of PVT with anticoagulant therapy can be beneficial for certain patients with cirrhosis.

While some studies demonstrate the possible benefits of anticoagulants in the setting of cirrhosis to prevent PVT, the field needs to design more trials to evaluate the effects of prophylactic anticoagulation in patients who are at risk for developing PVT. Importantly, the field needs to clearly define which patients are at the highest risk for the development of PVT, and define what the absolute contraindications for anticoagulation in the setting of cirrhosis are. Child–Pugh B and C decompensated state is most likely to benefit from anticoagulant therapy, although this will likely depend on flow state and preexisting prothrombotic tendencies. However, randomized controlled trials are necessary to help set treatment and prophylaxis guidelines. Currently, there are multiple DOACs that are available that are used to prevent and treat thrombotic events. The data for their use in patients with cirrhosis are relatively sparse while the preliminary experience suggests that they are safe and effective (–Table 3). There is no evidence to suggest any particular DOAC for patients with CTP-A cirrhosis. Based on scant data from several clinical trials, and on pharmacodynamics properties, it appears that apixaban would be the preferred DOAC in patients with CTP-B cirrhosis. Apixaban has a favorable DILI profile compared with other DOACs and has minimal changes in its pharmacodynamics in CTP-B patients. Recommendations for use of DOACs in patients with cirrhosis-associated thrombocytopenia are based solely on expert opinion given the paucity of data in this group. We are reluctant to initiate DOACs in a patient with a cirrhosis-associated PVT if the platelet count is less than 50,000 cells/μL and use considerable caution if the platelet count is between 50,000 and 80,000 cells/μL.

The traditional experience with warfarin and LMWH is being vigorously challenged by both the patient and treating community and there is a considerable push toward the use of DOACs given their safety and efficacy, and the relative less need for monitoring of adequacy of anticoagulation, in patients with cirrhosis. While we recommend well-designed and randomized trials to demonstrate their safety and efficacy so that we can establish concrete guidelines on their use in those with cirrhosis who have thrombotic events or who are at-risk for clotting manifestations, it is unlikely that we will see properly done trials comparing DOACs with LMWH and warfarin with the intention of assessing their comparative safety and efficacy. Thus, as it stands now and with the data available, it is reasonable to consider DOACs as an alternative in patients with compensated cirrhosis and without severe thrombocytopenia, both as prophylaxis and as treatment of thrombosis.

Main Concepts and Learning Points

• While the large trials that led to the approval of DOACs excluded patients with cirrhosis, based on limited studies and pharmacokinetics, DOACs appear to be as safe and efficacious as traditional anticoagulants in patients with compensated cirrhosis, while more studies are needed in patients with decompensated cirrhosis to determine the optimal drug and dose in this patient population.
• A small number of trials and case series demonstrate that DOACs are effective in the treatment of acute portal vein thrombosis and may have superior efficacy compared with vitamin–K antagonists.
• Preclinical studies suggest antifibrotic effects of thrombin and factor Xa inhibition in liver disease models, indicating that there may be an additional role for DOACs in patients with cirrhosis aside from treatment of splanchnic venous thrombosis and thromboembolism.

Conflicts of Interest

E.M.W. has no disclosures. J.P. has no disclosures. K.R.R. discloses research support (paid to the University of Pennsylvania) from AbbVie, Merck, Gilead, and Bristol-Myers Squibb. K.R.R. is also on the Scientific Advisory Board for AbbVie, Gilead, and Merck on Hepatitis C therapeutic area.

References


Kassel KM, Sullivan BP, Cui W, Copple BL, Luyendyk JP. Therapeutic administration of the direct thrombin inhibitor argatroban reduces hepatic inflammation in mice with established fatty liver disease. Am J Pathol 2012;181(04):1287–1295


71 Mendell J, Johnson L, Ridout G, He L, Chen S. An open-label phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics. Eur Heart J 2012;33(S1):Abstract 2024


73 Clinicaltrials NIH. gov. The Effect of Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixaban, an Oral FXa Antagonist. Available at: https://clinicaltrials.gov/ct2/show/NCT03397888 Accessed September 24, 2018


76 Hum J, Shatzel JJ, Jou JH, Deloughrey TG. The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis. Eur J Haematol 2017;98(04):393–397


101 Coleman CI, Peacock WF, Bunz TJ, Alberts MJ. Effectiveness and safety of apixaban, dabigatran, and rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and previous stroke or transient ischemic attack. Stroke 2017;48(08):2142–2149
117 De Gottardi A, Garcia-Fagan JC; VALDIG Investigators. The anticoagulant efficacy of rivaroxaban may be attenuated in cirrhotic patients. Liver Int 2017;37(08):1252